Abstract
The 2017 Global Initiative for Chronic Obstructive Lung Disease guidelines for the evaluation and management of chronic obstructive pulmonary disease revise the assessment tool used to evaluate patients, implement a new pharmacologic algorithm focusing on escalation/de-escalation therapy, and recommend new combination inhaled medications. The guidelines also address nonpharmacologic treatments and the importance of identifying and properly managing comorbidities. This article highlights these important changes to clinical practice.
MeSH terms
-
Administration, Inhalation
-
Adrenergic beta-Agonists / administration & dosage
-
Algorithms
-
Bronchodilator Agents / administration & dosage
-
Comorbidity
-
Delayed-Action Preparations
-
Diagnosis, Differential
-
Disease Progression
-
Drug Monitoring
-
Drug Therapy, Combination
-
Exercise
-
Exercise Therapy
-
Humans
-
Muscarinic Antagonists / administration & dosage
-
Nutritional Support
-
Oxygen Inhalation Therapy
-
Patient Education as Topic
-
Practice Guidelines as Topic*
-
Pulmonary Disease, Chronic Obstructive / diagnosis
-
Pulmonary Disease, Chronic Obstructive / epidemiology
-
Pulmonary Disease, Chronic Obstructive / rehabilitation
-
Pulmonary Disease, Chronic Obstructive / therapy*
-
Risk Assessment
-
Smoking Cessation
Substances
-
Adrenergic beta-Agonists
-
Bronchodilator Agents
-
Delayed-Action Preparations
-
Muscarinic Antagonists